All Posts: aging
-
First Large Study Details Cognitive Outcomes Among Older Breast Cancer Patients
The first large U.S. study of cognition in older breast cancer patients, led by researchers from Georgetown Lombardi Comprehensive Cancer Center, indicates that within the first two years after diagnosis and treatment, most women do not experience cancer-related cognitive problems.
Category: News Release
-
Cures Within Reach Funds Huntington’s Disease Clinical Trial with Nilotinib at Georgetown
Georgetown University Medical Center announces a clinical trial testing the safety of the repurposed cancer drug nilotinib in Huntington’s disease. This is the fourth clinical trial of the drug for a neurodegenerative disorder.
Category: News Release
-
Georgetown University Medical Center Selected as Lewy Body Dementia Research Center of Excellence
The Lewy Body Dementia Association has designated Georgetown University Medical Center as a “Research Center of Excellence.” GUMC joins 23 other centers chosen for their clinical expertise in Lewy body dementia, experience running clinical trials in related conditions, their facility’s capacity and willingness to participate, and their geographic locations.
Category: News Release
-
Taking a Broad Look at Aging
With collaboration from teaching faculty across the campus, Georgetown University will launch the new master’s in aging & health program in this fall. The new program goes beyond geriatrics to the study of aging well in today’s society.
Category: GUMC Stories
-
Some Cancer Therapies May Provide a New Way to Treat High Blood Pressure
Drugs designed to halt cancer growth may offer a new way to control high blood pressure (hypertension), say Georgetown University Medical Center investigators. The finding could offer an advance in hypertension treatment.
Category: News Release
-
Agent Clears Toxic Proteins, Reduces Inflammation and Improves Cognition in Neurodegeneration Models
LONDON (July 16, 2017) — Researchers have found cell receptors abnormally overexpressed in post-mortem brains of those with Parkinson’s and Alzheimer’s diseases, and that they can be inhibited in animal models to clear toxic protein buildup, reduce brain inflammation, and improve cognitive performance. These dual findings, presented by Georgetown University Medical Center (GUMC) researchers at […]
Category: News Release
-
Steroid Originally Discovered in the Dogfish Shark Attacks Parkinson’s-Related Toxin in Animal Model
A naturally occurring steroid made by the dogfish shark prevents the buildup of a lethal protein in animal studies, reports an international team of researchers. The clustering of this protein, alpha-synuclein (α-synuclein), is the hallmark of Parkinson’s disease and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.
Category: News Release
-
Nobel Prize-winning Science is Key to Georgetown Neurotherapeutic Research
Today, the 2016 Nobel Prize in the category of medicine or physiology was awarded to Yoshinori Ohsumi “for his discoveries of mechanisms for autophagy,” a fundamental process for degrading and recycling cellular components.
Category: GUMC Stories
-
Georgetown Receives FDA Clearance to Conduct Clinical Trial with Nilotinib in Alzheimer’s Disease
Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer’s disease.
Category: News Release
-
Resveratrol Appears to Restore Blood-Brain Barrier Integrity in Alzheimer’s Disease
TORONTO (July 27, 2016) — Resveratrol, given to Alzheimer’s patients, appears to restore the integrity of the blood-brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. The reduction in neuronal inflammation slowed the cognitive decline of patients, […]
Category: News Release